Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2013

01-11-2013 | Original Article

Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia

Authors: Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim

Published in: Digestive Diseases and Sciences | Issue 11/2013

Login to get access

Abstract

Background

The advantage of the quantitative fecal immunochemical test (FIT) is the flexibility to set the positivity threshold. However, the diagnostic success of the FIT has not been compared for standard and low cut-off thresholds.

Aims

The purpose of this study was to compare the diagnostic success of FIT for standard and low cut-off thresholds.

Methods

In 2009 and 2010 a standard cut-off threshold (20 μg Hb/g feces) was used as positivity criterion for the FIT; in 2012 a low cut-off (10 μg Hb/g feces) was used. Diagnostic success was compared between the two groups.

Results

Of the total of 14,289 participants, 195 (1.4 %) had positive FIT results. Positivity of the FIT was significantly higher in the low cut-off group than in the standard cut-off group (1.8 vs. 1.0 %, p = 0.000). Although detection of advanced neoplasia lesions was comparable, proximal neoplasia was more frequently detected in the low cut-off group (33.3 vs. 20.9 %, p = 0.016). With the low cut-off threshold, 39 (0.7 %) participants were also classified as having positive results, and 18 (46.2 %) of these had colorectal neoplasias. The number of positive results from the FIT was increased by 54.9 %, and detection of advanced neoplasia was increased by 60 % with the low cut-off threshold compared with the standard cut-off.

Conclusions

A low cut-off threshold for the FIT resulted in better detection of proximal neoplasia in population-based screening. These results indicate the cut-off threshold for positive FIT should be properly chosen and adjusted in colorectal cancer screening.
Literature
1.
go back to reference Choi KS, Jun JK, Lee HY, Hahm MI, Oh JH, Park EC. Increasing uptake of colorectal cancer screening in Korea: a population-based study. BMC Public Health.. 2010;10:265.PubMedCrossRef Choi KS, Jun JK, Lee HY, Hahm MI, Oh JH, Park EC. Increasing uptake of colorectal cancer screening in Korea: a population-based study. BMC Public Health.. 2010;10:265.PubMedCrossRef
2.
go back to reference Shim JI, Kim Y, Han MA, et al. Results of colorectal cancer screening of the national cancer screening program in Korea, 2008. Cancer Res Treat.. 2010;42:191–198.PubMedCrossRef Shim JI, Kim Y, Han MA, et al. Results of colorectal cancer screening of the national cancer screening program in Korea, 2008. Cancer Res Treat.. 2010;42:191–198.PubMedCrossRef
3.
go back to reference Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening of colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst. 1993;85:1311–1318.PubMedCrossRef Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening of colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst. 1993;85:1311–1318.PubMedCrossRef
4.
go back to reference Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–1607.PubMedCrossRef Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–1607.PubMedCrossRef
5.
go back to reference Atkin WS, Cuzick J, Northover JM, Whynes DK. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet. 1993;341:736–740.PubMedCrossRef Atkin WS, Cuzick J, Northover JM, Whynes DK. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet. 1993;341:736–740.PubMedCrossRef
6.
go back to reference Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for faecal occult blood. N Engl J Med. 1993;328:1365e71. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for faecal occult blood. N Engl J Med. 1993;328:1365e71.
7.
go back to reference Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.PubMedCrossRef Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.PubMedCrossRef
8.
go back to reference Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.PubMedCrossRef Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.PubMedCrossRef
9.
go back to reference Jørgensen OD, Kronborg O, Fenger C. A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002;50:29–32.PubMedCrossRef Jørgensen OD, Kronborg O, Fenger C. A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002;50:29–32.PubMedCrossRef
10.
go back to reference Young GP, St John DJ, Winawer SJ, Rozen P; WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy). Choice of fecal occult blood test for screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroenterol. 2002;97:2499–2507. Young GP, St John DJ, Winawer SJ, Rozen P; WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy). Choice of fecal occult blood test for screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroenterol. 2002;97:2499–2507.
11.
go back to reference Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer. 2009;100:259–265.PubMedCrossRef Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer. 2009;100:259–265.PubMedCrossRef
12.
go back to reference Leiberman DA, Holub J, Eisen G, Kraemer D, Morris CD. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc. 2005;62:875–883.CrossRef Leiberman DA, Holub J, Eisen G, Kraemer D, Morris CD. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc. 2005;62:875–883.CrossRef
13.
go back to reference Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210–214.PubMedCrossRef Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210–214.PubMedCrossRef
14.
go back to reference Fenocchi E, Martinez L, Tolve J, et al. Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test. Eur J Cancer Prev. 2006;15:384–390.PubMedCrossRef Fenocchi E, Martinez L, Tolve J, et al. Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test. Eur J Cancer Prev. 2006;15:384–390.PubMedCrossRef
15.
go back to reference Rubeca T, Rapi S, Confortini M, et al. Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series. Int J Biol Markers.. 2006;21:157–161.PubMed Rubeca T, Rapi S, Confortini M, et al. Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series. Int J Biol Markers.. 2006;21:157–161.PubMed
16.
go back to reference Grazzini G, Gastiglione G, Ciabattoni C, et al. Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev. 2004;13:19–26.PubMedCrossRef Grazzini G, Gastiglione G, Ciabattoni C, et al. Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev. 2004;13:19–26.PubMedCrossRef
17.
go back to reference Sohn DK, Jeong SY, Choi HS, et al. Single immunochemical fecal occult blood test for detection of colorectal neoplasia. Cancer Res Treat.. 2005;37:20–23.PubMedCrossRef Sohn DK, Jeong SY, Choi HS, et al. Single immunochemical fecal occult blood test for detection of colorectal neoplasia. Cancer Res Treat.. 2005;37:20–23.PubMedCrossRef
18.
go back to reference Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of an quantitative immunochemical test for faecal occult blood. J Med Screen. 2002;9:99–103.PubMedCrossRef Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of an quantitative immunochemical test for faecal occult blood. J Med Screen. 2002;9:99–103.PubMedCrossRef
19.
go back to reference Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average-risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105:2017–2025.PubMedCrossRef Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average-risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105:2017–2025.PubMedCrossRef
20.
go back to reference Omata F, Shintani A, Isozaki M, et al. Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals. Eur J Gastroenterol Hepatol. 2011;23:1036–1041.PubMed Omata F, Shintani A, Isozaki M, et al. Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals. Eur J Gastroenterol Hepatol. 2011;23:1036–1041.PubMed
21.
go back to reference Rozen P, Levi Z, Hazazi R, et al. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther. 2009;29:450–457. Rozen P, Levi Z, Hazazi R, et al. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther. 2009;29:450–457.
22.
23.
go back to reference Cha JM, Lee JI, Joo KR, Shin HP, Park JJ. Telephone reminder call in addition to mailing notification improved the acceptance rate of colonoscopy in patients with a positive fecal immunochemical test. Dig Dis Sci. 2011;56:3137–3142.PubMedCrossRef Cha JM, Lee JI, Joo KR, Shin HP, Park JJ. Telephone reminder call in addition to mailing notification improved the acceptance rate of colonoscopy in patients with a positive fecal immunochemical test. Dig Dis Sci. 2011;56:3137–3142.PubMedCrossRef
24.
go back to reference Fraser CG, Allison JE, Halloran SP, Young GP. Expert working group on fecal immunochemical tests for hemoglobin, colorectal cancer screening committee, world endoscopy organization. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012;104:810–814.PubMedCrossRef Fraser CG, Allison JE, Halloran SP, Young GP. Expert working group on fecal immunochemical tests for hemoglobin, colorectal cancer screening committee, world endoscopy organization. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012;104:810–814.PubMedCrossRef
25.
go back to reference Terhaarsive Droste JS, Oort FA, van der Hulst RW, et al. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev. 2011;20:272–280. Terhaarsive Droste JS, Oort FA, van der Hulst RW, et al. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev. 2011;20:272–280.
26.
go back to reference Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol. 2010;105:682–690.PubMedCrossRef Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol. 2010;105:682–690.PubMedCrossRef
27.
go back to reference Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244–255.PubMedCrossRef Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244–255.PubMedCrossRef
28.
go back to reference Wilschut JA, Hol L, Dekker E, et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology. 2011;141:1648–1655.PubMedCrossRef Wilschut JA, Hol L, Dekker E, et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology. 2011;141:1648–1655.PubMedCrossRef
29.
go back to reference Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Dis Colon Rectum. 2011;54:876–886.PubMedCrossRef Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Dis Colon Rectum. 2011;54:876–886.PubMedCrossRef
30.
go back to reference Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428.PubMed Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428.PubMed
31.
go back to reference Haug U, Kuntz KM, Knudsen AB, et al. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs. right-sided colorectal neoplasia. Br J Cancer. 2011;104:1779–1785.PubMedCrossRef Haug U, Kuntz KM, Knudsen AB, et al. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs. right-sided colorectal neoplasia. Br J Cancer. 2011;104:1779–1785.PubMedCrossRef
32.
go back to reference Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer: a population-based, case-control study. Ann Intern Med. 2009;150:1–8.PubMedCrossRef Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer: a population-based, case-control study. Ann Intern Med. 2009;150:1–8.PubMedCrossRef
33.
go back to reference Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med. 2011;154:22–30.PubMedCrossRef Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med. 2011;154:22–30.PubMedCrossRef
34.
go back to reference Van Rossum LG, Van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and fecal immunochemical blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.PubMedCrossRef Van Rossum LG, Van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and fecal immunochemical blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.PubMedCrossRef
35.
go back to reference Van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol.. 2011;9:333–339.PubMedCrossRef Van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol.. 2011;9:333–339.PubMedCrossRef
36.
go back to reference Cha JM, Lee JI, Joo KR, et al. Performance of the fecal immunochemical test is not decreased by high ambient temperature in the rapid return system. Dig Dis Sci. 2012;57:2178–2183.PubMedCrossRef Cha JM, Lee JI, Joo KR, et al. Performance of the fecal immunochemical test is not decreased by high ambient temperature in the rapid return system. Dig Dis Sci. 2012;57:2178–2183.PubMedCrossRef
37.
go back to reference Cha JM, Lee JI, Joo KR, Shin HP, Park JJ. Telephone reminder call in addition to mailing notification improved the acceptance rate of colonoscopy in patient with a positive fecal immunochemical test. Dig Dis Sci. 2011;56:3137–3142.PubMedCrossRef Cha JM, Lee JI, Joo KR, Shin HP, Park JJ. Telephone reminder call in addition to mailing notification improved the acceptance rate of colonoscopy in patient with a positive fecal immunochemical test. Dig Dis Sci. 2011;56:3137–3142.PubMedCrossRef
Metadata
Title
Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia
Authors
Jae Myung Cha
Joung Il Lee
Kwang Ro Joo
Hyun Phil Shin
Jung Won Jeun
Jun Uk Lim
Publication date
01-11-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2819-2

Other articles of this Issue 11/2013

Digestive Diseases and Sciences 11/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.